Fig. 3
3-year overall survival related to achievement of CMR (dotted line) or not CMR (continuous line) after intensified treatment with eBEACOPP or BEACOPP-14.
Fig. 3 | Blood Cancer Journal
3-year overall survival related to achievement of CMR (dotted line) or not CMR (continuous line) after intensified treatment with eBEACOPP or BEACOPP-14.
